APA (7th ed.) Citation

Kenis, C., Ponde, N., Decoster, L., de Azambuja, E., Jerusalem, G., Neven, P., . . . Wildiers, H. (2019). 385TiP - RIBOB: A study on the efficacy and safety of ribociclib in combination with letrozole in older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior systemic therapy for advanced disease. Annals of Oncology, 30, v140. https://doi.org/10.1093/annonc/mdz242.080

Chicago Style (17th ed.) Citation

Kenis, C., et al. "385TiP - RIBOB: A Study on the Efficacy and Safety of Ribociclib in Combination with Letrozole in Older Women (≥70 Years) with Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) with No Prior Systemic Therapy for Advanced Disease." Annals of Oncology 30 (2019): v140. https://doi.org/10.1093/annonc/mdz242.080.

MLA (9th ed.) Citation

Kenis, C., et al. "385TiP - RIBOB: A Study on the Efficacy and Safety of Ribociclib in Combination with Letrozole in Older Women (≥70 Years) with Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) with No Prior Systemic Therapy for Advanced Disease." Annals of Oncology, vol. 30, 2019, p. v140, https://doi.org/10.1093/annonc/mdz242.080.